Skip to main content

Table 1 PICO for study inclusion

From: Effects of vitamin D supplementation on fasting glucose, dyslipidemia, blood pressure, and abdominal obesity among patients with metabolic syndrome: a protocol for systematic review and meta-analysis of randomized controlled trials

Participants (P) Intervention (I) Comparison (C) Outcomes (O)
Inclusion criteria
 Participants with MetS diagnosed by NCEP-ATP III (1), or IDF (2) criteria, aged ≥ 18 years, and with inadequate vitamin D status Vitamin D supplementation in the form of vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol) at any dose, given orally, daily, weekly, or monthly RCTs with intervention compared to placebo Fasting glucose levels (mg/dL), triglyceride levels (mg/dL), waist circumference (cm), mean blood pressure (mmHg), and HDL- C (mg/dL) (two or more outcomes will be considered in subgroup analyses)
Exclusion criteria
 Participants with MetS aged under 18 years Vitamin D supplements with other vitamin and chemical element supplements; vitamin D supplementation in fortified foods as the amount of vitamin cannot be defined accurately; studies that used active vitamin D supplementation (1.25-dihydroxy vitamin D)   
  1. MetS metabolic syndrome, NCEP-ATPIII National Cholesterol Education Program Adult Treatment Panel III, IDF International Diabetes Federation, RCTs randomized controlled trials adapted from Mousa et al. [20]